Bioregulator dossier · 2 · draft

Livagen

A four-amino-acid peptide (Lys-Glu-Asp-Gly) sold in Russia as a hepatoprotective. Thin PubMed footprint; the CyberLeninka record is the deeper source.

Index › Evidence › Livagen

1 · Identity

Identity: sequence-only / literature
Aliases: KEDG tetrapeptide (EN); Livagenum (EN); Ливаген (RU_LATIN)

2 · Mechanism — what the primary literature actually shows

Confidence: very low

Polypeptide fraction from bovine liver (Khavinson school lineage). The mechanism is liver-tissue-specific regenerative — but no DIRECT studies on Livagen® product were found in the CyberLeninka audit. Most adjacent literature covers hepatocyte circahourly protein metabolism rhythms (Feldman 2011), immune regulation, infectious immunology, elderly ophthalmology care. The Khavinson-school liver peptide concept is real but lacks dedicated primary literature. This is a research gap, not a confirmed null finding.

How it works

Key findings (5)

Adjacent: circahourly protein metabolism rhythms in hepatocytes (Feldman-Rozhkova 2011)
Adjacent: immune regulation, infectious immunology (textbook references 2001, 2003)
Adjacent: Roncoleukin + colostral immunity in newborn calves — bovine peptide bioregulation paradigm (Russian agricultural literature)
Adjacent: Drosophila peptide study (Mylnikov 2008) — genotype × peptide interaction in longevity
No DIRECT Livagen® product studies identified in CyberLeninka audit

Evidence quality

Very low. No direct primary literature. The compound exists in the Khavinson peptide family but is under-researched.

Open questions (3)

Is there any dedicated pharmacology for Livagen® as a drug?
Liver-tissue-specific regeneration — what would be the analogous model to prostatilen/prostate?
Comparison with hepatoprotectors (e.g. ademethionine, UDCA) — has this been done?

3 · Summary

18 papers · 0 A · 0 B · 13 C · 5 ungraded · 7 COI-flagged · 2001–2023 · 0 Cyrillic titles

Design distribution

18 linked papers · categorical count

Design	Count	Distribution
CONTROLLED	3	███
CLINICAL_UNCONTROLLED	5	█████
ANIMAL	3	███
IN_VITRO	2	██
UNGRADED	5	█████

4 · Possible mechanisms — candidate list

corroborated · partial · hypothesized · contested

4 candidate mechanisms · 1 partial evidence · 3 hypothesized

M-01

Polypeptide fraction from bovine liver (Khavinson school lineage)

Very low. No direct primary literature. The compound exists in the Khavinson peptide family but is under-researched.

STATE hypothesized IN_VITROANIMALCLINICAL_UNCONTROLLED

M-02

Adjacent: circahourly protein metabolism rhythms in hepatocytes

From scientist synthesis key finding 1: Adjacent: circahourly protein metabolism rhythms in hepatocytes (Feldman-Rozhkova 2011)

STATE partial evidence IN_VITROANIMAL

M-03

Adjacent: immune regulation, infectious immunology

From scientist synthesis key finding 2: Adjacent: immune regulation, infectious immunology (textbook references 2001, 2003)

STATE hypothesized IN_VITROANIMAL

M-04

Adjacent: Roncoleukin + colostral immunity in newborn calves — bovine peptide bioregulation paradigm

From scientist synthesis key finding 3: Adjacent: Roncoleukin + colostral immunity in newborn calves — bovine peptide bioregulation paradigm (Russian agricultural literature)

STATE hypothesized IN_VITROANIMAL

5 · Pathways — questions the corpus does not yet answer

each pathway is a question · tied to a candidate · blocked by a specific barrier

3 pathways

P-01

Is there any dedicated pharmacology for Livagen® as a drug?

candidate M-01 · would shift: Resolution would shift mechanism M-01 from very low confidence.

system · in_vitro + animal + clinical

Pathway: Falsification experiment for open question 1. Is there any dedicated pharmacology for Livagen® as a drug?
Blocked by: See synthesis evidence quality section for barriers.

P-02

Liver-tissue-specific regeneration — what would be the analogous model to prostatilen/prostate?

candidate M-01 · would shift: Resolution would shift mechanism M-01 from very low confidence.

system · in_vitro + animal + clinical

Pathway: Falsification experiment for open question 2. Liver-tissue-specific regeneration — what would be the analogous model to prostatilen/prostate?
Blocked by: See synthesis evidence quality section for barriers.

P-03

Comparison with hepatoprotectors (e.g. ademethionine, UDCA) — has this been done?

candidate M-01 · would shift: Resolution would shift mechanism M-01 from very low confidence.

system · in_vitro + animal + clinical

Pathway: Falsification experiment for open question 3. Comparison with hepatoprotectors (e.g. ademethionine, UDCA) — has this been done?
Blocked by: See synthesis evidence quality section for barriers.

6 · Bibliography — Russian primary sources

CyberLeninka / disserCat / Russian patents · cited raw, no grading CyberLeninka PDFs · inventor detail · first publication

Inventor (detail): V.Kh. Khavinson + S.V. Trofimova (ophthalmology), St. Petersburg Institute. | V.Kh. Khavinson lab.

First publication: late 2000s / early 2010s (Khavinson 2011 review). | mid-2000s.

Peptide kind: Polypeptide fraction from retinal / ocular tissue (porcine or bovine); often combined with Retinalamin. | Polypeptide fraction from ovarian tissue (bovine).

Below: substantive excerpts from 3 Russian primary papers. Click each title to expand the Russian/English abstract.

3/6 papers with substantive abstracts · 3,083 characters of Russian/English pharmacological text extracted · 3 Russian abstracts · 2 English abstracts · 1/6 relevance-classified.

Extracted findings (0 models · 1 mechanism terms · direction: ↑0 ↓0 ↺0 across 3 papers)

Model organisms: —
Doses / concentrations: —
Mechanism terms: антиоксидантный
Effect direction: 0× increase · 0× decrease · 0× restoration/normalisation

[2011] Околочасовые ритмы белкового метаболизма в гепатоцитах при различных экзогенных воздействиях

○ adjacent

Authors: Фельдман Бронислав Владимирович, Рожкова Ирина Семеновна

Journal: Астраханский медицинский журнал

Аннотация научной статьи по фундаментальной медицине, автор научной работы — Фельдман Бронислав Владимирович, Рожкова Ирина Семеновна Околочасовые клеточные ритмы белкового метаболизма являются фундаментальным свойством клетки и выполняют важную роль в процессах адаптации к изменяющимся условиям окружающей среды. При различных формах естественного гипобиоза, искусственной гипотермии и токсическом воздействии происходит модификация околочасовых осцилляций, связанная с нарушением морфофункциональной организации, как на клеточном, так и тканевом уровнях

PDF →

[2016] Формирование колострального иммунитета и становление неспецифической резистентности у новорожденных телят под действием

○ adjacent

Authors: Кляпнев А.В.

Journal: Ветеринарный врач

FORMATION OF COLOSTRAL IMMUNITY AND NON-SPECIFIC RESISTANCE IN NEWBORN CALVES TREATED WITH RONCOLEUKIN The aim of the present studies was to determine a possible effect of Roncoleukin on accumulation of immunoglobulins and other immunogenic factors in the mammary gland of cows before calving, their discharge as a part of colostrum, as well as the influence of these factors on the formation of colostrums-driven immunity and nonspecific resistance in newborn calves . 20 down-calving cows of black-motley breed selected for its analogues were the objects of the experimental studies. The cows from the experimental group were subcutaneously injected once with Roncoleukin at dosage of 0.5 у 3-6 days before calving. The control animals were injected subcutaneously with a physiological sodium chloride solution using the same scheme. Blood was taken for research in newborn calves at 6 hours and 10th day after birth. At six hours after birth the calves born to cows from the experimental group showed a significant increase in the number of red blood cells + 14.37% (P<0.05), white blood cells +22.37% (P<0.05) on account of lymphocytes, the level of total protein was up to 12.74%, especially albumin fractions + 13.12% (P<0.05) and Y-globulins + 16.1% (P<0.05); hemoglobin level was higher for20.68% (P<0.05) comparing to the control animals. Another blood test performed at 10 days after birth showed that the difference in the studied blood parameters remained the same. The experimental calve...

PDF →

[2008] Влияние пептидов на антиоксидантный статус и параметры кривых выживания селектируемых инбредных линий Drosophila melanog

○ adjacent

Authors: Мыльников С. В., Опарина Т. И., Малинин В. В.

Journal: Экологическая генетика

Аннотация научной статьи по биологическим наукам, автор научной работы — Мыльников С. В., Опарина Т. И., Малинин В. В. Проведен сравнительный анализ влияния шести синтетических пептидов, а также эпиталамина и мелатонина на параметры кривых выживания, и антиоксидантный статус тканей D. melanogaster. Выявлен значительный вклад генотипа и взаимодействия генотип среда в изучаемые показатели. Показано, что механизмы влияния вилона и эпиталона на генерацию активных форм кислорода в митохондриях различаются.

PDF →

7 · Bibliography — PubMed corpus

top 15 by grade then year · PMID links outbound to pubmed.ncbi.nlm.nih.gov

PMID	Year	Design	n	Grade	COI	Title
32362099	2020	IN_VITRO	—	[C]	coi	[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.].
28574395	2017	CLINICAL_UNCONTROLLED	—	[C]	—	[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].
25341254	2014	CLINICAL_UNCONTROLLED	—	[C]	—	[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patien
25541832	2014	CONTROLLED	—	[C]	—	[Genomic instability in atherosclerosis].
24423684	2013	CLINICAL_UNCONTROLLED	—	[C]	—	[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].
18830022	2008	CLINICAL_UNCONTROLLED	—	[C]	—	[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age
17460203	2007	CONTROLLED	—	[C]	—	Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.
16075683	2005	CONTROLLED	—	[C]	coi	[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
15085253	2004	CLINICAL_UNCONTROLLED	—	[C]	coi	Effects of short peptides on lymphocyte chromatin in senile subjects.
12942748	2003	IN_VITRO	—	[C]	coi	[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].
12096446	2002	ANIMAL	—	[C]	coi	[Tissue-specific action of peptides in tissue culture of rats of various ages].
15926314	2001	ANIMAL	—	[C]	coi	[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
11713572	2001	ANIMAL	—	[C]	coi	Tissue-specific effects of peptides.
37042594	2023	—	—	—	—	EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
17921545	2007	—	—	—	—	[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].

8 · Corroboration

Corpus source: PubMed (eutils) and OpenAlex, swept against this compound by PMID. Last verified 26.08.2026.
Identity source: PubChem CID — verified live. InChIKey —. Live fetch on 26.08.2026.
Provenance: St. Petersburg Institute of Bioregulation and Gerontology (2002) Khavinson VKh — Liver tetrapeptide; hepatoprotective

9 · Open questions

2 items

Zero A- or B-grade evidence in the corpus. No registered RCT with disclosed n.
Most of the published evidence for this compound is from the group that developed it. Where independent replication exists, we flag it in the mechanism block above; where it doesn't, treat mechanism claims as developer-side.